Qanatpharma

What Qanatpharma does

Qanatpharma is a clinical-stage biopharmaceutical company developing mechanism-based therapies for diseases in which microvascular dysfunction is a primary driver of progression, with an initial focus on heart failure (cognitive impairment in HFrEF) and subarachnoid hemorrhage (delayed cerebral ischemia). The company was founded in Switzerland in 2020 following a Series A round, and is headquartered in Stans, Switzerland with research and development operations in Toronto, Canada (the primary hub for target identification, drug discovery, and clinical trials through the Toronto Centre for Microvascular Medicine) and Munich, Germany (the home of its AI and machine-learning drug discovery team under Director Dr. Philipp Trepte).

The scientific platform is the proprietary Arteriome system, which integrates bioengineering, microvascular phenotyping, multi-omic profiling, disease modeling, computational biology, and AI to decode resistance artery function and dysfunction. The lead clinical program, LYRIC-HF, is a randomized, placebo-controlled, double-blind Phase 2 proof-of-concept trial repositioning lumacaftor (a CFTR-stabilizing compound originally approved in cystic fibrosis combination therapy) to restore cerebral blood flow autoregulation in HFrEF patients, with recruitment at St. Michael's Hospital Toronto under Principal Investigator Dr. Kim Connelly. Follow-on programs include GENESiS-SAH and GENESiS-HF (proprietary new chemical entities developed via a generative-AI discovery collaboration with Zuse Institute Berlin, Enamine, and Proteros biostructures) and RESiST-HF (a proprietary biologic for heart failure). The company holds Orphan Drug Designation from both the FDA and EMA (2020) for CFTR-corrector treatment of subarachnoid hemorrhage.

The company is pre-revenue. There are no commercial products, no disclosed pricing, and no licensing income; future revenue is expected to come from pharmaceutical product sales following regulatory approvals. Current commercial activity consists of clinical trial recruitment conducted through academic medical centers (St. Michael's Hospital and University Health Network, Toronto) and discovery collaborations with academic and industry partners. The company is backed by private investors (angel and Series A), and senior leadership combines deep microvascular domain expertise (founder/CSO Dr. Steffen-Sebastian Bolz, University of Toronto) with heavyweight pharma operating experience (Chairman Stefan Oschmann, former CEO of Merck KGaA).

Name

Qanatpharma

Legal name

Qanatpharma AG

Website

https://qanatpharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Qanatpharma is a clinical-stage biopharma company developing therapies that target resistance artery dysfunction to treat heart failure, subarachnoid hemorrhage, and related microvascular diseases, with operations in Switzerland, Canada, and Germany.

Ownership category

akta.pro rank

Product category

Microvascular Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

Keywords

• Microvascular therapeutics
• Cardiovascular drug development
• Resistance artery research
• Clinical-stage biopharma
• Generative-AI drug discovery

Headquarters

HQ city

Stans

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Qanatpharma is a clinical-stage biopharma company with no commercial products yet. The company is developing therapies for microvascular dysfunction in cardiovascular diseases. Revenue will be generated through pharmaceutical product sales following regulatory approvals. Current programs include LYRIC-HF (lumacaftor repositioning for heart failure), GENESiS-SAH (proprietary NCE for subarachnoid hemorrhage), GENESiS-HF (proprietary NCE for heart failure), and RESiST-HF (proprietary biologic for heart failure).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Qanatpharma is a clinical-stage biopharma company developing innovative therapies for diseases where microvascular dysfunction is a central feature, with a focus on resistance artery biology and the myogenic response mechanism. The company operates the proprietary Arteriome discovery platform and is advancing a pipeline that includes the LYRIC-HF Phase 2 clinical program repositioning lumacaftor for cognitive impairment in heart failure, GENESiS generative-AI driven small molecule discovery programs for cerebrovascular conditions, and the RESiST-HF biologic program for heart failure.

Product overview

Qanatpharma is a clinical-stage biopharma company developing a portfolio of microvascular therapies centered on resistance artery biology. The core Arteriome Platform integrates bioengineering, multi-omic profiling, and AI-driven target identification to discover novel therapeutics. The lead clinical program, LYRIC-HF, is repositioning lumacaftor for cognitive impairment in heart failure. Follow-on programs include GENESiS-SAH and GENESiS-HF (proprietary NCEs targeting cerebrovascular conditions via generative-AI drug discovery) and RESiST-HF (a novel biologic for heart failure). The pipeline spans from target discovery and validation through preclinical studies to clinical trials, managed within a collaborative ecosystem involving Toronto Centre for Microvascular Medicine, Zuse Institute Berlin, Enamine, and Proteros biostructures.

Differentiator

Problem solved

Functional benefit

Products and services

• LYRIC-HF Phase II proof-of-concept clinical trial repositioning lumacaftor (a CFTR-stabilizing compound) to restore cerebral blood flow and improve cognitive function in heart failure patients with reduced ejection fraction (HFrEF). Targeted at the LYRIC-HF trial at St. Michael's Hospital in Toronto with Dr. Kim Connelly as Principal Investigator.
• Arteriome Platform Proprietary end-to-end discovery and translational research platform integrating bioengineering, microvascular phenotyping, multi-omic profiling, disease modeling, computational biology, and artificial intelligence to decode resistance artery function and dysfunction. The first comprehensive and deeply integrated framework assembled to decipher the molecular and cellular basis of resistance artery function and dysfunction.
• GENESiS-SAH Generative-AI guided drug discovery program developing first-in-class small molecule therapies to prevent delayed cerebral ischemia (DCI) following subarachnoid hemorrhage, targeting a protein involved in regulating cerebrovascular resistance.
• GENESiS-HF Follow-on proprietary new chemical entity (NCE) program expanding on the LYRIC-HF cerebrovascular treatment approach for cognitive impairment in heart failure patients, utilizing generative-AI driven drug design.
• RESiST-HF Proprietary biologic approach to reduce cardiac injury after heart failure, differentiating QP's pipeline with a novel therapeutic modality targeting microvascular dysfunction.
• Lumacaftor Monosubstance (Investigational) Repositioned CFTR-stabilizing compound originally approved for cystic fibrosis (in combination drug Orkambi), being developed as a microvascular therapy for cerebral blood flow deficits in heart failure and subarachnoid hemorrhage. Phase 1 trial demonstrated bioequivalence to Orkambi reference product with favorable safety profile.

Quantifiable outcome

• Phase 1 trial demonstrated bioequivalence of lumacaftor monotherapy to Orkambi reference product with favorable safety profile
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• Zuse Institute Berlin (ZIB)coreTechnology or Integration · 9 July 2025International discovery collaboration harnessing AI-powered drug discovery for cerebrovascular conditions. ZIB brings deep expertise in high-performance computing, ligand docking, and AI-based generative ligand design, developing proprietary algorithms for the GENESiS-SAH and GENESiS-HF programs targeting cerebral perfusion deficits.
• Enamine Ltd.coreTechnology or Integration · 9 July 2025World's largest supplier of make-on-demand small molecules providing REAL-directed compound synthesis for the generative-AI driven drug discovery collaboration. Enamine's unique access to ultra-large chemical space via the REAL approach and unparalleled compound libraries (4.7 million in stock, 350,000 building blocks) enables rapid translation of virtual hits into novel chemical matter.
• Proteros biostructures GmbHcoreTechnology or Integration · 9 July 2025Munich-based structure-based drug discovery provider with cutting-edge platform to unlock technically challenging drug targets. Proteros leverages its drug discovery platform including structural biology and cryo-EM to validate hit compounds and deliver Qualified Hits Lead Series with fully characterized Mode-of-Action enabling downstream Lead Optimization.
• Centre for Microvascular Medicine (CMM)coreStrategic or Co-development Partner · 28 May 2024Multidisciplinary initiative at University of Toronto's Translational Biology and Engineering Program at the Ted Rogers Centre for Heart Research advancing microvascular research, training, and clinical applications. CMM discovery program spans from cells to animal models, translation to human tissues, and ultimately clinical applications. QP coordinates with CMM for Toronto Centre for Microvascular Medicine research collaboration.
• University of TorontocoreStrategic or Co-development PartnerFormalized research agreement to support preclinical research at the Bolz lab, which is equipped with technical expertise to conduct validation experiments in specific microvascular beds and several disease models. The Toronto university-hospital network provides access to top-tier research talent and clinical infrastructure.
• Ted Rogers Centre for Heart ResearchcoreStrategic or Co-development PartnerStrategic research partnership supporting microvascular research and clinical programs. Home to the Centre for Microvascular Medicine and provides clinical research infrastructure for proof-of-concept studies linking microvascular mechanisms to human clinical endpoints.
• St. Michael's Hospital, Unity Health TorontoflagshipStrategic or Co-development PartnerPrimary clinical trial site for LYRIC-HF Phase 2 proof-of-concept trial. Dr. Kim Connelly serves as Principal Investigator. The hospital is part of Toronto's world-class clinical ecosystem supporting proof-of-concept studies.
• University Health Network (UHN)coreStrategic or Co-development PartnerRecruiting centre for LYRIC-HF clinical trial. UHN's Peter Munk Cardiac Centre provides cardiovascular research expertise and patient access for clinical studies.

Scale indicators5 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Tenax Therapeutics: Tenax Therapeutics is a clinical-stage specialty pharma developing levosimendan and TNX-103 for pulmonary hypertension and heart failure with preserved ejection fraction — directly comparable to Qanatpharma as a clinical-stage developer of CV drugs targeting HF populations.
• Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage biotechnology company developing AAV-based gene therapies for cardiovascular diseases, including Friedreich's ataxia cardiomyopathy and arrhythmogenic cardiomyopathy — directly comparable as a clinical-stage CV biotech with a differentiated mechanistic approach.
• Keros Therapeutics: Keros Therapeutics is a clinical-stage biopharma developing therapies targeting TGF-β superfamily signaling for hematologic and cardiovascular disorders (e.g., cibotercept for CKD anemia, hypertension programs). Comparable to Qanatpharma as a clinical-stage CV-focused biotech.
• Cytokinetics: Cytokinetics is a late-stage clinical biopharma developing cardiac myosin modulators (e.g., omecamtiv mecarbil, aficamten) for heart failure with reduced and preserved ejection fraction — directly comparable to Qanatpharma as a clinical-stage cardiovascular drug developer targeting HF populations.
• Tenaya Therapeutics: Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies and precision medicines for heart failure and other cardiovascular diseases — directly comparable as a small-cap clinical-stage CV biotech with a mechanistically differentiated pipeline.
• Mineralys Therapeutics: Mineralys is a clinical-stage biopharma developing aldosterone synthase inhibitors (lorundrostat) for resistant hypertension and cardiovascular disease. It is comparable to Qanatpharma as a similarly sized clinical-stage CV biotech targeting microvascular/hypertension mechanisms.
• Edgewise Therapeutics: Edgewise Therapeutics is a clinical-stage biopharma developing cardiac and muscular disease therapies (e.g., EDG-5506 for Becker muscular dystrophy and CV programs). It is comparable to Qanatpharma as a similarly sized clinical-stage company with cardiovascular and muscle-focused mechanism programs.
• Vicore Pharma Holding: Vicore Pharma is a clinical-stage Swedish biopharma developing C21 (an angiotensin II type 2 receptor agonist) for IPF, COVID-19 lung disease, and associated cardiopulmonary indications. Comparable as a clinical-stage European biotech with mechanism-based CV/respiratory programs.

Emerging players

• ProKidney: ProKidney is a clinical-stage biotechnology company developing cell therapies (rilparencel) for chronic kidney disease, with overlapping emphasis on microvascular and renal pathophysiology. Comparable as a clinical-stage emerging biotech addressing microvascular-driven organ dysfunction.

Broad incumbents

• Aerpio Pharmaceuticals: Aerpio Pharmaceuticals is a clinical-stage biopharma historically focused on microvascular dysfunction and Tie2/VE-PTP modulation in ophthalmology and cardiovascular indications. It is comparable to Qanatpharma as an earlier-stage microvascular-focused biopharma working on similar resistance-vessel biology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/qanatpharma
• LinkedInlinkedin.com/company/qanatpharma
• Instagraminstagram.com/qanatpharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qanatpharma